Concepedia

Laurie Catley

LC

Statistics

Publications

5

Citations

1.9K

H-Index

5

Active since

2005

Affiliations

Dana-Farber Cancer Institute(Current)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Brigham and Women's Hospital

Boston Children's Hospital

Laurie Catley is an author at Dana-Farber Cancer Institute specializing in bcr-abl inhibitors, medicine, and bcr-abl1 fusion gene.

Publications per year

2005–2007

5

Publications

5

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

, , +6

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

Ellen Weisberg, Laurie Catley, Renee D. Wright et al. · Blood · 2006 · 106 citations · Full text

, , +7

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 105 citations · Full text

, , +6

Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity

Ellen Weisberg, Renee D. Wright, Jingrui Jiang et al. · Gastroenterology · 2006 · 93 citations

, , +13

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

Ellen Weisberg, Andrew L. Kung, Renee D. Wright et al. · Molecular Cancer Therapeutics · 2007 · 78 citations

, , +17

1–5 of 5